Suppr超能文献

目前对消费品中大麻二酚的益处、安全性和监管的理解。

The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products.

机构信息

Center for Research on Ingredient Safety, Michigan State University, East Lansing, MI, 48824, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, 48824, USA.

Hyman, Phelps & McNamara, P.C., Washington, D.C, 20005, USA.

出版信息

Food Chem Toxicol. 2021 Nov;157:112600. doi: 10.1016/j.fct.2021.112600. Epub 2021 Oct 6.

Abstract

The popularity of cannabidiol (CBD) in consumer products is soaring as consumers are using CBD for general health and well-being as well as to seek relief from ailments especially pain, inflammation, anxiety, depression, and sleep disorders. However, there are limited data currently in the public domain that provide support for these benefits. By contrast, a significant amount of safety evaluation data for CBD have been obtained recently from pre-clinical and clinical studies of the CBD therapeutic Epidiolex®. Yet some key data gaps concerning the safe use of CBD still remain. Furthermore, current regulations on CBD use in consumer products remain uncertain and often conflict between the state and federal level. In light of the rapidly expanding popularity of CBD-related products in the marketplace, here we review the current understanding of the benefits, safety, and regulations surrounding CBD in consumer products. This review does not advocate for or against the use of CBD in consumer products. Rather this review seeks to assess the state-of-the-science on the health effects and safety of CBD, to identify critical knowledge gaps for future studies, and to raise the awareness of the current regulations that govern CBD use in consumer products.

摘要

随着消费者将大麻二酚 (CBD) 用于一般健康和福祉,以及寻求缓解疼痛、炎症、焦虑、抑郁和睡眠障碍等疾病,其在消费产品中的受欢迎程度正在飙升。然而,目前在公共领域中,支持这些益处的数据有限。相比之下,最近从 CBD 治疗药物 Epidiolex®的临床前和临床研究中获得了大量关于 CBD 的安全性评估数据。然而,关于 CBD 安全使用的一些关键数据差距仍然存在。此外,目前关于 CBD 在消费产品中的使用的法规仍然不确定,并且在州和联邦层面经常存在冲突。鉴于 CBD 相关产品在市场上的迅速普及,在这里我们回顾了有关 CBD 在消费产品中的益处、安全性和法规的当前理解。本综述不主张或反对在消费产品中使用 CBD。相反,本综述旨在评估 CBD 的健康影响和安全性的科学现状,确定未来研究的关键知识空白,并提高对目前监管 CBD 在消费产品中使用的法规的认识。

相似文献

引用本文的文献

2
Prevalence of cannabidiol use and correlates in U.S. adults.美国成年人中使用大麻二酚的流行情况及其相关因素。
Drug Alcohol Depend Rep. 2024 Oct 9;13:100289. doi: 10.1016/j.dadr.2024.100289. eCollection 2024 Dec.
6
Comprehensive Insight into Cutaneous Application of Hemp.对大麻皮肤应用的全面洞察。
Pharmaceutics. 2024 May 31;16(6):748. doi: 10.3390/pharmaceutics16060748.
8
Perceptions and Opinions on Cannabidiol in the Orthopaedic Sports Medicine Community.骨科运动医学领域对大麻二酚的认知与看法
Orthop J Sports Med. 2023 Sep 21;11(9):23259671231191766. doi: 10.1177/23259671231191766. eCollection 2023 Sep.

本文引用的文献

1
The Trouble with CBD Oil.大麻二酚(CBD)油的问题。
Med Cannabis Cannabinoids. 2018 Jun 12;1(1):65-72. doi: 10.1159/000489287. eCollection 2018 Jun.
3
Immune Responses Regulated by Cannabidiol.大麻二酚调节的免疫反应。
Cannabis Cannabinoid Res. 2020 Feb 27;5(1):12-31. doi: 10.1089/can.2018.0073. eCollection 2020 Mar 1.
8
Use of cannabidiol in anxiety and anxiety-related disorders.使用大麻二酚治疗焦虑及相关障碍。
J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):253-261. doi: 10.1016/j.japh.2019.11.008. Epub 2019 Dec 19.
9
Inflammation and the dimensions of depression: A review.炎症与抑郁的维度:综述。
Front Neuroendocrinol. 2020 Jan;56:100800. doi: 10.1016/j.yfrne.2019.100800. Epub 2019 Oct 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验